These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22334941)

  • 1. Big pharma's struggles might benefit health plans.
    Manag Care; 2012 Jan; 21(1):65. PubMed ID: 22334941
    [No Abstract]   [Full Text] [Related]  

  • 2. Bad medicine. Big Pharma's cash injections lead to poor ethical outcomes.
    Sloane T
    Mod Healthc; 2006 Aug; 36(31):19. PubMed ID: 16958350
    [No Abstract]   [Full Text] [Related]  

  • 3. States combat drug costs.
    Consum Rep; 2002 Dec; 67(12):8-9. PubMed ID: 12448442
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmaceuticals issue brief: pharmaceutical assistance programs: year end report--2004.
    Seay M
    Issue Brief Health Policy Track Serv; 2004 Dec; ():1-26. PubMed ID: 15724309
    [No Abstract]   [Full Text] [Related]  

  • 5. The evolving pharmacy benefit market.
    Navarro RP
    Med Interface; 1994 May; 7(5):65-7, 70. PubMed ID: 10134345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When success sours: PBMs under scrutiny.
    Carroll J
    Manag Care; 2002 Sep; 11(9):20-6. PubMed ID: 12369344
    [No Abstract]   [Full Text] [Related]  

  • 7. Don't pay too much for generic fills. Pass-through pricing is a good way for a payer to realize the benefit of increased prescribing of generic drugs.
    Cahn LJ
    Manag Care; 2010 Nov; 19(11):21-7. PubMed ID: 21141372
    [No Abstract]   [Full Text] [Related]  

  • 8. Employer strategies in managing prescription drug costs.
    Rubinstein E
    Bus Health; 1991 Jan; 9(1):26, 28-30, 34-5. PubMed ID: 10108955
    [No Abstract]   [Full Text] [Related]  

  • 9. Prescription drug prices in Canada.
    Gross D
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123
    [No Abstract]   [Full Text] [Related]  

  • 10. New standard for pharmacy benefits.
    Walgran CC
    J Health Care Benefits; 1994; 3(3):60-4. PubMed ID: 10131221
    [No Abstract]   [Full Text] [Related]  

  • 11. Doubts emerge about drug industry mergers.
    Bus Health; 1994 Nov; 12(11):53-4, 56, 61. PubMed ID: 10138536
    [No Abstract]   [Full Text] [Related]  

  • 12. How will biotechnology fare in pharma's big plan?
    Nat Biotechnol; 1996 Nov; 14(11):1515. PubMed ID: 9634811
    [No Abstract]   [Full Text] [Related]  

  • 13. Big Pharma's Commedia.
    Steele FR
    Cell; 2005 Dec; 123(6):971-3. PubMed ID: 16360023
    [No Abstract]   [Full Text] [Related]  

  • 14. Monitoring drug compliance can reduce total medical plan costs.
    Mandelker J
    Bus Health; 1993 May; 11(6):26-7, 31-5. PubMed ID: 10126109
    [No Abstract]   [Full Text] [Related]  

  • 15. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The need for health care reform.
    Mossinghoff GJ
    Health Syst Rev; 1994; 27(3):5-6. PubMed ID: 10134516
    [No Abstract]   [Full Text] [Related]  

  • 17. Employers push to manage prescription drug costs.
    Frieden J
    Bus Health; 1992 May; 10(6):43-6, 48, 50. PubMed ID: 10119119
    [No Abstract]   [Full Text] [Related]  

  • 18. Shifting gears.
    Tweed V
    Bus Health; 1994 May; 12(5):28-9, 32, 34 passim. PubMed ID: 10134334
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-cutting ideas: prescription drugs.
    Fish JL
    J Health Care Benefits; 1993; 3(1):10-3. PubMed ID: 10130342
    [No Abstract]   [Full Text] [Related]  

  • 20. Disease management. Getting out from under drug companies' shadows.
    Heimoff S
    Manag Care; 2000 Mar; 9(3):39-40, 42-3. PubMed ID: 11066212
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.